In Vivo Spectroscopy vis-à-vis Ex Vivo Spectroscopy: Pearls and Pitfalls: Imaging Review

Khizer Razak, Surbhi Gupta and Meena GL*
Department of Radiodiagnosis, S.P. Medical College, Bikaner, Rajasthan, India
*Corresponding author: Meena GL, Department of Radiodiagnosis, S.P. Medical College, Bikaner, Rajasthan, India, Tel: +919413143709; E-mail: meenabkn@yahoo.co.in

Received date: November 15, 2017; Accepted date: November 27, 2017; Published date: December 05, 2017

Abstract

Aims and objective: The objective of this communication is to bring the metabolomics by magnetic resonance (high resolution spectroscopy) to the clinical radiologist and compare the spectroscopy in vivo (NMR spectroscopy used in clinical) with the high resolution spectroscopy ex vivo (magic angle spectroscopy, HR –MORE). S and analyzing differences, advantages and limitations of each technique in different tissues.

Review of the topic: In vivo spectroscopy that is usually performed in the clinic is a non-invasive technique that can provide important information for the diagnosis and monitoring of different lesions. The most well-known applications of in vivo spectroscopy today are those carried out by localized 1H spectroscopy, monovoxel or multivoxel (spectroscopic image), brain, prostate or breast. There are other modalities, such as the 31P or 13C spectroscopy, but they are much less frequent and are only carried out in a few specialized centres. Without any doubt, the most widespread clinical use is confined to the central nervous system.

Conclusion: The in vivo spectroscopy provides important metabolic information for the diagnosis of different pathologies, non-invasively, however, this technique has certain limitations, such as low spectral resolution, that is, the number of metabolites that can be identified/quantified; which results in low diagnostic specificity.

Ex vivo spectroscopy, however, has a spectral resolution and sensitivity far superior to in vivo techniques, which allows detecting a large number of metabolites, and therefore greatly improves its diagnostic capacity. However, we must not forget that it is an invasive technique, since it is based on the analysis of pieces of tissue (biopsies, surgical pieces...) and therefore loses its usefulness in those lesions that are impossible to biopsy. In conclusion, each technique has its added value and its limitations and it is the correct use of them and the combination of them with other diagnostic parameters, where their clinical potential resides.

Keywords: Spectroscopy; Imaging; Peak; Cerebral; Diagnosis; Prostate

Introduction

The high-resolution spectroscopy used in metabolomics studies is a technique in which high-field vertical spectrometers (11-23 T) are used for the analysis of biofluids or small pieces of intact tissue (for example biopsies), obtaining spectroscopic results of multiple metabolites that are not visible by in vivo spectroscopy [1].

In this communication we will focus on the technique that analyzes intact tissue, known as HR-MAS, from the English high resolution magic angle spinning (Figure 1).

HR-MAS spectroscopy has much higher sensitivity and resolution than in vivo spectroscopy, which allows determining the metabolic profile or "metabolic fingerprint" of a tissue sample of between 5 and 20 mg. The spectral resolution is comparable to that obtained in liquid spectroscopy, from tissue extracts, with the great advantage that it does not require any manipulation of the sample and therefore the tissue can be recovered and reused later for diagnosis in pathological anatomy (Figure 2).
Figure 2: Ex vivo HR-MAS spectroscopy has great sensitivity and resolution compared to in vivo spectroscopy, which allows determining the metabolic fingerprint of an intact tissue sample, while in vivo spectroscopy only it allows to solve a few metabolites.

The most well-known applications of in vivo spectroscopy today are those carried out by localized 1H spectroscopy, monovoxel or multivoxel (spectroscopic image), brain, prostate or breast. There are other modalities, such as the 31 P or 13 C spectroscopy, but they are much less frequent and are only carried out in a few specialized centres.

Currently, ex vivo spectroscopy is not implemented in hospitals, but its research results promise an interesting future for the diagnosis and management of patients.

Background and Discussion

Without any doubt, the most widespread clinical use of spectroscopy confined to the central nervous system. The main metabolites used in diagnosis in the CNS are shown in Figure 3.

**Figure 3:** 1H monovoxel spectrum in vivo of healthy brain tissue in which the main metabolites that can be observed in this type of studies are indicated.

NAA (N-Acetyl Aspartic)- Neuronal Marker. Its decrease reflects a neuroaxonal impoverishment (typical in glial tumors).

ml (myoinositol)- Glial marker Its increase reflects an increase in the glial contribution [in glial tumors it is indicative of low grade tumor]. Its decrease indicates glial de-differentiation (high-grade tumors)

Cho (Colina)- Membrane Metabolism. In Tumors, it is a Proliferative Activity Indicator. Increases in demyelination and inflammatory processes

Cr (Creatine)- Marker of Energy Metabolism. It is typically diminished in malignant tumors (high grade)

Mobile lipids- Malignancy marker (necrosis). It is not usually talk about malignancy unless they are present. They also appear with radiotherapy treatment (radionecrosis).

Lac (Lactate)- Marker of Anaerobic Metabolism. Typical of active tumors against quiescent tumors. It also appears in hypoxic/ischemic and infectious/inflammatory processes.

Regarding the prostate, the number of metabolites observed is lower:

Citrate- Marker of prostatic glandular tissue without alterations. It drastically decreases in adenocarcinomas.

Cho (Hill) - Proliferative activity marker. It increases in adenocarcinomas.

Polyamines. Like citrate, its presence is an indicator of normal glandular metabolism and is diminished in adenocarcinomas.

Finally, in the breast, given the large contribution of lipid signals, which make it difficult to observe most metabolites in vivo, the only metabolite used for tumor diagnosis is choline, which rises significantly in tumors.

Spectroscopy by HR-MAS ex vivo on its side has the advantage of having a high sensitivity and spectral resolution which allows the detection of multiple metabolites not visible by spectroscopy in vivo, therefore, the diagnostic specificity is much higher. For example, in vivo spectroscopy only resolves a peak in the area of choline-derived metabolites, while HR-MAS allows its different components to be separated: Phosphocholine (PC) Glycerophosphocholine (GPC) and Choline (Cho) (Figures 4 and 5).

Bibliographic review of the results of in vivo spectroscopy compared to high resolution spectroscopy ex vivo and the contribution in the diagnosis of different pathologies of both techniques, in particular in three tumor types: cerebral, prostate and breast.

**Cerebral**

In vivo spectroscopy: In vivo spectroscopy at the brain level has shown its usefulness in tumor evaluation, for which several metabolites have been measured: NAA, Cho, lactate, creatine and myoinositol (Figure 3)

Cho levels increase in a multitude of tumors, but at the brain level, their levels are significantly higher when the tumor is present, therefore they are useful for differentiating gliomas of low, high grade and benign cerebral pathology.
NAA (N-Acetyl Aspartic acid) decreases in those pathologies in which there is neuroaxonal impoverishment, as occurs in glial tumors [2].

**Ex vivo spectroscopy:** The HR-MAS at the brain level is able to quantify a multitude of metabolites that are not visible by conventional spectroscopy in vivo.

Martinez-Bisbal et al. performed HR-MAS spectrum of high-grade glioma biopsies, determining 37 metabolites [3].

On the other hand it has been shown that there is a good correlation of in vivo and ex vivo diagnosis with the only exception that metabolites related to anaerobic metabolism, lactate and alanine are increased in ex vivo, due to the period of hypoxia experienced by tissue pieces until they are frozen [3].

In a study published in 2009, it was determined that the different levels of the components of the peak of total choline (tCho), GPC (glycerophosphocholine), PC (phosphocholine) and Cho (free Choline) and the relationship between these, is different according to whether of gliomas of low or high grade. Thus, in low-grade gliomas, the predominant component is GPC whereas in high-grade gliomas PC predominates [4] (Figure 5).

On the other hand, there seems to be a correlation between certain metabolites detected by HR-MAS and tumor grading. Thus, the increase in the PC/GPC ratio is characterized by severe forms of glioblastoma multiforme. And an increase in the ratio of myoinositol/Cho allows differentiating the clinical evolution of different low-grade gliomas [5].

The usefulness of HR-MAS for the differential diagnosis between aggression of meningiomas has also been demonstrated, it was determined that the glutamine and glutamate metabolites that are related to the metabolism of glutathione are significantly more increased in more aggressive meningiomas and with greater possibility therefore of recurrence [6].

**Prostate**

In vivo spectroscopy: In the prostate, in vivo spectroscopy using endorectal MRI with multivoxel technique has proved very useful for the diagnosis of prostate cancer. The prostatic epithelial cells have the peculiarity of producing a large amount of citrate under normal conditions, as a consequence of an inhibition of the zinc-mediated enzyme aconitase. However, when tumor transformation occurs, this inhibition is lost and citrate levels fall drastically (Figure 6). On the other hand, as in other tumor processes, choline increases significantly.

This technique has proved to be very useful in cases of elevated PSA to locate areas of tumor suspicion and thus direct biopsy to a specific area (Figure 7). On the other hand, in cases of radiotherapy treatment, prostate spectroscopy is very useful for the diagnosis of local recurrence, since after the treatment the prostate tissue presents an anodyne appearance and the imaging techniques are not very informative. However, spectroscopy allows observing the peak of choline in those areas where there is recurrence [7].

Ex vivo spectroscopy: The determination of ex vivo metabolites that are not resolved by in vivo spectroscopy has provided relevant information in prostate cancer. Thus, it has been determined that malignant and non-malignant tissue can be differentiated using the ratios of the GPC (Glycerophosphocholine)+PC (phosphocholine) and Creatine spectra.
In addition it has been determined that hills derivatives are better tumor biomarkers than citrate itself, especially in the central prostate, since citrate appears high in prostatic epithelial cells and low in tumor, but also appears low in stroma. However, the hills appear high only in tumor tissue (twenty).

On the other hand it has been seen that the Citrate/Creatine relationship is significantly related to tumor aggressiveness (twenty). Finally, it is interesting to mention the work of Asten et al. in which it is demonstrated that the prostate biopsy tissue is not altered after the analysis by HR-MAS, so it can be used for histological diagnosis [8].

Breast

In vivo spectroscopy: The elevation of the choline peak, as in other types of cancer, is used as a biomarker of tumor activity, however, caution should be used with this statement since, as has been shown in several publications, the elevation of choline may be due to also to other pathologies of benign character, in particular fibroadenomas, tubular adenomas and during lactation [9-12].

On the other hand, the quantification of this metabolite by in vivo spectroscopy has shown its usefulness in determining the response to treatment before clinical response data appear. Thus, there are studies that indicate that 24H after treatment with doxorubicin, there are significant changes of the choline peak in the tumor lesion and that the decrease in the peak at 24H is associated with a better response to treatment [3-5,7,10,11,13-18].

Ex vivo spectroscopy: As in other tissues, ex vivo spectroscopy allows the analysis of many non-visible metabolites by in vivo spectroscopy, which raises the possibility of establishing a diagnosis of tumor aggressiveness based on the metabolic profile or metabolome. This is especially attractive in the case of the breast because in vivo spectroscopy poses great difficulties due to the abundance of lipids in the breast tissue, which make it extremely difficult to carry out routinely (Figure 8).

![Figure 6: Citrate signal as observed in vivo at 1.5 T and table of concentration in different tissues.](image)

![Citrate levels in Human Prostate Gland (nmol/g)](table)

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Zone</td>
<td>5.000</td>
</tr>
<tr>
<td>Peripheral Zone</td>
<td>13.000</td>
</tr>
<tr>
<td>Prostatic Fluid</td>
<td>40.000 - 150.000</td>
</tr>
<tr>
<td>BPH (mixed tissue)</td>
<td>10.000 - 15.000</td>
</tr>
<tr>
<td>BPH (glandular tissue)</td>
<td>20.000 - 50.000</td>
</tr>
<tr>
<td>PC (mixed tissue)</td>
<td>1.000 - 3.000</td>
</tr>
<tr>
<td>PC (malignant tissue)</td>
<td>&lt; 500</td>
</tr>
<tr>
<td>Stromal Tissue</td>
<td>150 - 300</td>
</tr>
<tr>
<td>Other soft tissues</td>
<td>150 - 450</td>
</tr>
<tr>
<td>Blood Plasma</td>
<td>90 - 110</td>
</tr>
</tbody>
</table>

![Figure 7: Spectroscopic image (or multivoxel spectroscopy) of prostate in vivo.](image)

The spectrum corresponding to the tumor zone (red) shows an increase of the choline peak and decrease of citrate compared to the spectrum of a healthy zone (green). The histological section is also shown in which it is confirmed that the alteration of the metabolic profile corresponds to a tumor nodule.
Conclusion

The in vivo spectroscopy provides important metabolic information for the diagnosis of different pathologies, non-invasively, however, this technique has certain limitations, such as low spectral resolution, that is, the number of metabolites that can be identified/quantified, which results in low diagnostic specificity.

Ex vivo spectroscopy, however, has a spectral resolution and sensitivity far superior to in vivo techniques, which allows detecting a large number of metabolites, and therefore greatly improves its diagnostic capacity. However, we must not forget that it is an invasive technique, since it is based on the analysis of pieces of tissue (biopsies, surgical pieces...) and therefore loses its usefulness in those lesions that are impossible to biopsy.

The results obtained in the studies published for the metabolomic study of breast cancer promise a very prosperous future for this type of techniques with a possible application in clinical settings.

On the other hand, there is an important connection with the radiological diagnosis since it is a spectroscopic study of the tissues, something that the radiologist already does in his day to day in the study by in vivo NMR [20,21]. On the other hand, this technique has great advantages with respect to its rapid realization without tissue destruction, which could be analyzed anatopomorphologically later, so it is not risky to think that the HR-MAS diagnosis is applied in a clinical setting in a short time and that be the radiologist in charge of its interpretation.

For its final translation to the clinic it is necessary to improve the spectral analysis system, so that it is automatic, robust and precise. With regard to breast cancer, it has been shown that there is a metabolomic pattern of breast cancer: increased lactate, glycine and PC (phosphocholine). The case of the typical pattern of the hills is significantly elevated in cases of positive ER (Estrogen Receptor), and in the determination of involvement of surgical borders, as well as in mouse models for cancer with luminal-like pattern, which raises a diagnosis of tumor aggressiveness of a metabolic spectrum.

Especially interesting is the possibility of metabolomic analysis of breast biopsies that would be performed in a short time and without tissue destruction. As we have commented, the studies carried out so far with breast biopsies have not been very solid, so further studies are needed to determine the diagnostic, evolutionary and subsequent management impact of each radiological pattern.

In conclusion, each technique has its added value and its limitations, and it is the correct use of them and the combination of them with other diagnostic parameters, where their clinical potential resides.

References


